Mirum Pharmaceuticals, Inc. (MIRM) shares rallied 7.3% in the last trading session to close at $43.33. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 21.9% gain over the past four weeks.Last week, the FDA approved a label expansion for the company’s lead drug, Livmarli, for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) aged 12 months and above as ...